Genmab A/S (GMAB) to Release Earnings on Tuesday

Genmab A/S (NASDAQ:GMAB) is anticipated to announce its Q4 2025 results before the market opens on Tuesday, February 17th. Analysts expect the company to announce earnings of $0.44 per share and revenue of $1.0560 billion for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, February 17, 2026 at 12:00 PM ET.

Genmab A/S Trading Up 1.5%

Shares of Genmab A/S stock opened at $30.03 on Friday. Genmab A/S has a 12-month low of $17.24 and a 12-month high of $35.43. The company has a market cap of $19.29 billion, a price-to-earnings ratio of 12.78, a PEG ratio of 17.63 and a beta of 0.90. The company’s 50-day moving average price is $32.35 and its 200-day moving average price is $29.71.

Hedge Funds Weigh In On Genmab A/S

Several hedge funds have recently bought and sold shares of the business. CIBC Private Wealth Group LLC increased its stake in Genmab A/S by 291.9% in the fourth quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock worth $25,000 after purchasing an additional 616 shares during the period. NewEdge Advisors LLC increased its stake in Genmab A/S by 1,229.0% in the 3rd quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock worth $38,000 after buying an additional 1,143 shares during the period. Brown Brothers Harriman & Co. lifted its holdings in Genmab A/S by 143.4% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock valued at $41,000 after buying an additional 780 shares in the last quarter. Osaic Holdings Inc. boosted its position in Genmab A/S by 37.8% in the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after buying an additional 440 shares during the period. Finally, Advisory Services Network LLC bought a new position in Genmab A/S in the 3rd quarter worth about $54,000. Institutional investors own 7.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on GMAB. HC Wainwright restated a “buy” rating and set a $39.00 price objective on shares of Genmab A/S in a research report on Wednesday, January 28th. Zacks Research lowered Genmab A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 31st. Johnson Rice restated a “buy” rating on shares of Genmab A/S in a research report on Monday, October 27th. Wall Street Zen lowered Genmab A/S from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Finally, Truist Financial reiterated a “buy” rating and set a $48.00 target price (down previously from $49.00) on shares of Genmab A/S in a research report on Thursday, November 6th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Genmab A/S currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.33.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.